A study concerning a new possibility to develop a light-based surveillance modality for prematurely born infants has been published in the Journal of Biophotonics. The paper “Comparison of dermal versus internal light administration in human lungs using the TDLAS‐GASMAS technique – Phantom studies” written by Jim Larsson, Dennis Leander, Märta Lewander Xu, Vineta Fellman, Joakim Bood and Emilie Krite Svanberg describes how the light source in the TDL-GASMAS technique can be applied internally rather than from the skin surface and thus dramatically enhance the signal. The study uses a 3D printed phantom of a preterm born infant; mimicking the chest, the ribs, the lungs and the heart.

Please find the full article here:

https://onlinelibrary.wiley.com/doi/10.1002/jbio.201800350

Hanna Sjöström, CEO GPX Medical:

” The published article show-cases our ground-breaking innovation capacity. We are at the very forefront of development and on our way to improve the care of preterm born infants all over the world.”

Picture of the 3D printed phantom parts, mimicking the chest, the ribs, the lungs and the heart in scale of a small prematurely born infant.

About GPX Medical

GPX Medical AB was formed in 2016 as a subsidiary to GASPOROX AB (publ), with the aim to develop and commercialize medical applications of GASMAS technology. The company is owned to 60% by GASPOROX AB (publ) and to 40% by Norsk Elektro Optikk AS, and located in Lund, Sweden. Org. nbr. 559069-9012.

For investors

Please contact CEO Hanna Sjöström for investment opportunities:
hs@gpxmedical.se

Contact

GPX Medical AB
Maskinvägen 1
223 70 Lund
Sweden
info@gpxmedical.se